Diagnosis and management of bispecific T cell–engaging antibody toxicity: A primer for emergency physicians
1. 系统已在2025-03-08 13:51:45对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
MK Wattana, JW Rowland, A Qdaisat, H Levavi…
Cancer Treatment …, 2025
Elsevier
Background T-cell-engaging bispecific antibodies (BsAbs) are a newer type of immunotherapy designed to boost T-cell cytotoxicity. They are increasingly used in cancer treatment, with drugs currently being tested and authorized for treating both liquid and solid tumors. It's becoming more likely that emergency physicians and other acute care practitioners will treat patients experiencing adverse events related to bispecific antibodies, as these drugs are regularly given in the outpatient setting. Currently, BsAb-associated side …
